Anti-obesity Prescription Drugs
SKU
MRR-4358BACA7FD1
Region
Global
Publication Date
February 2024
Delivery
Immediate
2023
USD 6.22 billion
2030
USD 10.74 billion
2024
USD 6.71 billion
CAGR
8.12%
Anti-obesity Prescription Drugs Market by Drug Class (Bupropion & Naltrexone, Liraglutide, Lorcaserin), Age Group (Adult, Pediatric), Distribution Channel - Global Forecast 2024-2030

[197 Pages Report] The Anti-obesity Prescription Drugs Market size was estimated at USD 6.22 billion in 2023 and expected to reach USD 6.71 billion in 2024, at a CAGR 8.12% to reach USD 10.74 billion by 2030.

Anti-obesity Prescription Drugs Market
To learn more about this report, request a free sample copy
Anti-obesity Prescription Drugs Market - Global Forecast 2024-2030
To learn more about this report, request a free sample copy
FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-obesity Prescription Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-obesity Prescription Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-obesity Prescription Drugs Market, highlighting leading vendors and their innovative profiles. These include Alisier Drugs Pvt. Ltd., Arena Pharmaceuticals Ltd, Arrowhead Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Norgine BV, Novo Nordisk A/s, SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, VIVUS LLC, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Anti-obesity Prescription Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Bupropion & Naltrexone
    • Liraglutide
    • Lorcaserin
    • Orlistat
    • Phentermine & Topiramate
  • Age Group
    • Adult
    • Pediatric
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Anti-obesity Prescription Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-obesity Prescription Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Anti-obesity Prescription Drugs Market?
  4. What is the market share of the leading vendors in the Anti-obesity Prescription Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Anti-obesity Prescription Drugs Market?

  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & CoverageANTI-OBESITY PRESCRIPTION DRUGS MARKET SEGMENTATION & COVERAGE
    3. Years Considered for the Study
    4. Currency & PricingUNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
    5. Language
    6. Limitations
    7. Assumptions
    8. Stakeholders
  2. Research Methodology
    1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET RESEARCH PROCESS
    2. Define: Research Objective
    3. Determine: Research Design
    4. Prepare: Research Instrument
    5. Collect: Data Source
    6. Analyze: Data Interpretation
    7. Formulate: Data Verification
    8. Publish: Research Report
    9. Repeat: Report Update
  3. Executive Summary
    1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2023 VS 2030
  4. Market Overview
    1. IntroductionANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
    2. Anti-obesity Prescription Drugs Market, by RegionANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  5. Market Insights
    1. Market DynamicsANTI-OBESITY PRESCRIPTION DRUGS MARKET DYNAMICS
      1. Drivers
        1. Rising prevalence of obesity and related chronic diseases
        2. Growing unhealthy and sedentary lifestyle
        3. Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
      2. Restraints
        1. Side effect related to anti-obesity drugs
      3. Opportunities
        1. Introduction of novel anti-obesity drugs
        2. Accelerating awareness towards obesity management
      4. Challenges
        1. Availability of alternative treatment options
    2. Market Segmentation Analysis
    3. Market Trend Analysis
    4. Cumulative Impact of High Inflation
    5. Porter’s Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    6. Value Chain & Critical Path Analysis
    7. Regulatory Framework
  6. Anti-obesity Prescription Drugs Market, by Drug Class
    1. IntroductionANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
    2. Bupropion & NaltrexoneANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION & NALTREXONE, BY , 2018-2030 (USD MILLION)
    3. LiraglutideANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY , 2018-2030 (USD MILLION)
    4. LorcaserinANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY , 2018-2030 (USD MILLION)
    5. OrlistatANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY , 2018-2030 (USD MILLION)
    6. Phentermine & TopiramateANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE & TOPIRAMATE, BY , 2018-2030 (USD MILLION)
  7. Anti-obesity Prescription Drugs Market, by Age Group
    1. IntroductionANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
    2. AdultANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY , 2018-2030 (USD MILLION)
    3. PediatricANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY , 2018-2030 (USD MILLION)
  8. Anti-obesity Prescription Drugs Market, by Distribution Channel
    1. IntroductionANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    2. Hospital PharmacyANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY , 2018-2030 (USD MILLION)
    3. Online PharmacyANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY , 2018-2030 (USD MILLION)
    4. Retail PharmacyANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY , 2018-2030 (USD MILLION)
  9. Americas Anti-obesity Prescription Drugs Market
    1. Introduction
    2. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    3. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Argentina
    5. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    6. Brazil
    7. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    8. Canada
    9. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    10. Mexico
    11. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    12. United States
    13. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    14. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  10. Asia-Pacific Anti-obesity Prescription Drugs Market
    1. Introduction
    2. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    3. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Australia
    5. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    6. China
    7. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    8. India
    9. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    10. Indonesia
    11. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    12. Japan
    13. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    14. Malaysia
    15. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    16. Philippines
    17. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    18. Singapore
    19. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    20. South Korea
    21. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    22. Taiwan
    23. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    24. Thailand
    25. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    26. Vietnam
    27. VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  11. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market
    1. Introduction
    2. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    3. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Denmark
    5. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    6. Egypt
    7. EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    8. Finland
    9. FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    10. France
    11. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    12. Germany
    13. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    14. Israel
    15. ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    16. Italy
    17. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    18. Netherlands
    19. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    20. Nigeria
    21. NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    22. Norway
    23. NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    24. Poland
    25. POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    26. Qatar
    27. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    28. Russia
    29. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    30. Saudi Arabia
    31. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    32. South Africa
    33. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    34. Spain
    35. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    36. Sweden
    37. SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    38. Switzerland
    39. SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    40. Turkey
    41. TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    42. United Arab Emirates
    43. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
    44. United Kingdom
    45. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  12. Competitive Landscape
    1. FPNV Positioning MatrixANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
    2. Market Share Analysis, By Key PlayerANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023
    3. Competitive Scenario Analysis, By Key Player
  13. Competitive Portfolio
    1. Key Company Profiles
      1. Alisier Drugs Pvt. Ltd.
      2. Arena Pharmaceuticals Ltd
      3. Arrowhead Pharmaceuticals, Inc.
      4. Boehringer Ingelheim International GmbH
      5. Bristol-Myers Squibb Company
      6. Currax Pharmaceuticals LLC
      7. Eisai Co., Ltd
      8. F. Hoffmann-La Roche AG
      9. GlaxoSmithKline PLC
      10. Norgine BV
      11. Novo Nordisk A/s
      12. SHIONOGI & Co., Ltd.
      13. Takeda Pharmaceutical Company Limited
      14. VIVUS LLC
      15. Zydus Lifesciences Limited
    2. Key Product Portfolio
  1. Alisier Drugs Pvt. Ltd.
  2. Arena Pharmaceuticals Ltd
  3. Arrowhead Pharmaceuticals, Inc.
  4. Boehringer Ingelheim International GmbH
  5. Bristol-Myers Squibb Company
  6. Currax Pharmaceuticals LLC
  7. Eisai Co., Ltd
  8. F. Hoffmann-La Roche AG
  9. GlaxoSmithKline PLC
  10. Norgine BV
  11. Novo Nordisk A/s
  12. SHIONOGI & Co., Ltd.
  13. Takeda Pharmaceutical Company Limited
  14. VIVUS LLC
  15. Zydus Lifesciences Limited
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Anti-obesity Prescription Drugs Market
The Global Anti-obesity Prescription Drugs Market size was estimated at USD 6.22 billion in 2023 and expected to reach USD 6.71 billion in 2024.
The Global Anti-obesity Prescription Drugs Market to grow USD 10.74 billion by 2030, at a CAGR of 8.12%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.